In 2022, Shang et al. developed an artificial mimic of tyrosine hydroxylase (TH), the key enzyme of the catecholamines biosynthesis pathway, that converts tyrosine to L-DOPA, the common and widely used substance for PD therapy. This evidence concerns the gene TH and Parkinson disease.